All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for EISAI, INC. · human health care company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $50,000.00 income · posted Apr 20, 2025

Official filing document

Bills named in this filing 3

S 891
Bipartisan Health Care Act
HR 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
HCONRES 14
Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…

Lobbying activity 5

Budget/Appropriations

H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions.

Trade (domestic/foreign)

Issues related to supply chain and tariffs.

Health Issues

Regulatory and legislative health care issues, including: Alzheimer's drug development; drug pricing; Pandemic and All-Hazards Preparedness Act (PAHPA) including reauthorizing priority review vouchers; pharmaceutical scheduling; TRICARE coverage issues in FY2026 National Defense Authorization Act; PBM reform; S.891, Bipartisan Health Care Act.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; drug pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Taxation/Internal Revenue Code

Issues related to tax reform. Issues related to R&D tax credit.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.